Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Got me again from last week. Have donated about 3k to this POS. I hope others have/will enjoy it. Any wonder Im off penny's. Oh wait, I still have 5 billionpref. Im rich bitc-
Lord help me, Am I going to become a two time PAIM loser. Honestly, I entered at .0011 today(Late, I know), is this the shake or is it baked TIA and GLTA
GLTY, its going to 8 pre market, as instituions will dump all thats left. PFE will suck up SEPR... Its a falling bomb
NBIX is a shorts dream......
Time Served
ENGY hold your ground folks!
Looks like it Bill
Goooo IPRE
In some ENGY- Gluton for punishment
IPRE 9's up
Morning MOOOVERS!!
SUPG News
Press Release Source: SuperGen, Inc.
U.S. FDA Approves Dacogen(TM) (Decitabine) For Injection
Wednesday May 3, 7:00 am ET
- Dacogen(TM) Approved for Patients with all FAB Classifications of MDS -
- Commercial Launch Planned For Late May -
MINNEAPOLIS and DUBLIN, Calif., May 3 /PRNewswire-FirstCall/ -- MGI PHARMA, INC. (Nasdaq: MOGN - News) and SuperGen, Inc. (Nasdaq: SUPG - News) today announced that the U.S. Food and Drug Administration (FDA) has approved Dacogen(TM) (decitabine) for Injection. Dacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo, and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups. MGI PHARMA plans to make Dacogen commercially available during the second quarter of 2006.
ADVERTISEMENT
"The FDA approval of Dacogen marks an important advancement for patients who suffer from MDS," said John M. Bennett, M.D., Chair of The Myelodysplastic Syndromes Foundation. "Patients with this serious condition are often anemic, experience fatigue and weakness and, in certain cases with an increase in leukemic blast cells, MDS can result in bone marrow failure."
Results from a phase 3 clinical trial demonstrated an overall response rate of 21% in Dacogen-treated patients considered evaluable for response, defined as those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment, compared to 0% in the supportive care arm. All patients who responded to Dacogen treatment became or remained transfusion independent during the time of the response. The most commonly occurring adverse reactions with Dacogen include neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae, constipation, and diarrhea. It is recommended that patients be treated with Dacogen for a minimum of four cycles, and treatment may continue as long as the patient continues to benefit.
"The approval of Dacogen demonstrates MGI PHARMA's ability to identify, acquire, develop, and register promising products," said Lonnie Moulder, president and chief executive officer of MGI PHARMA. "We look forward to providing clinicians with an effective therapy to offer their MDS patients. MGI PHARMA is committed to continuing the development of Dacogen for patients with acute myeloid leukemia, chronic myelogenous leukemia, and solid tumors, in addition to developing alternative dosing regimens for patients with MDS."
"This approval is a significant milestone for SuperGen. Over the course of more than seven years, SuperGen developed Dacogen by working with scientists, clinicians, patient advocacy groups, and regulatory agencies to get this product approved for patients with MDS," said James S. Manuso, Ph.D., President and CEO of SuperGen. "The approval of Dacogen is a significant benefit for patients because of the drug's ability to address the underlying disease and, potentially, to improve patient outcomes."
Summary of Clinical Results
SuperGen conducted a randomized open-label, multicenter, controlled trial that evaluated 170 adult patients with myelodysplastic syndromes meeting FAB classification criteria and IPSS High-Risk, Intermediate-2 and Intermediate-1 prognostic scores. Eighty-nine patients were randomized to Dacogen therapy plus supportive care, 83 of whom received Dacogen, and 81 were randomized to supportive care alone. Dacogen was intravenously infused at a dose of 15 mg/m2 over a 3-hour period, every eight hours, for three consecutive days. Dacogen therapy was repeated every 6 weeks, depending on the patient's clinical response and toxicity. Supportive care consisted of blood and blood product transfusions, prophylactic antibiotics, and hematopoietic growth factors. Co-primary endpoints of the study were overall response rate (complete responses plus partial responses) and time to acute myeloid leukemia (AML) or death. Secondary endpoints included hematologic improvement, duration of response, cytogenetic response rate, transfusion requirements, quality of life, survival, and safety.
The overall response rate in the Dacogen study arm was 17% with a median response duration of 288 days, compared to 0% in the supportive care arm (p<0.001). A complete response rate of 9% and a partial response rate of 8% were observed in the Dacogen arm. The overall response rate was 21% in Dacogen-treated patients considered evaluable for response, defined as those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment. In addition, 13% of patients in the Dacogen arm had hematologic improvement, compared to 7% of patients in the supportive care arm.
Two additional open label, single arm, multicenter studies were conducted to evaluate the safety and efficacy of Dacogen in patients with MDS of any FAB subtype. The results of the phase 2 studies were consistent with the results of the phase 3 trial with overall response rates of 26% (N=66) and 24% (N=98).
"Dacogen represents a new treatment option that can reduce or eliminate the need for patients with MDS to receive frequent blood transfusions, which is an important clinical benefit," said Hagop Kantarjian, M.D., Professor and Chairman, Department of Leukemia, at the University of Texas MD Anderson Cancer Center and clinical investigator of the ongoing Dacogen clinical development program for MDS and AML. "This approval is a major advance in our fight against myelodysplastic syndromes."
Important Safety Information
Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential would be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for 2 months afterwards.
The most commonly occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit http://www.mgipharma.com for full prescribing information.
Ongoing Clinical Studies
MGI PHARMA is currently conducting a phase 3 pivotal trial to evaluate Dacogen in patients with AML. Additional phase 2 studies are also underway to evaluate alternative dosing regimens for Dacogen in patients with MDS and in patients with AML and chronic myelogenous leukemia, or CML. A phase 3 European Organization for Research and Treatment of Cancer- (EORTC-) sponsored study of Dacogen in patients with MDS is ongoing in Europe.
About MDS
SUPG Pre market
Nice-Im getting more "Defensive" for my long term investments. Beer, cigarettes, and macaroni and cheese-May i suggest- big MO (Altria) LOL, my favorite
Nice one Jae!!
SPMP.029x.03
:]
IPRE chomp chomp
BMGC News
BioMag Corporation Acquires Biospectrum Technologies, Inc., a Biomedical Company That Designs and Patents Diagnostic Equipment and Immunoassays
Monday May 1, 11:34 am ET
ORANGEVALE, Calif.--(BUSINESS WIRE)--May 1, 2006--BioMag Corporation (OTC:BMGC - News), announced today that it has acquired Biospectrum Technologies, Inc., a biomedical diagnostics company.
ADVERTISEMENT
BioMag Corp. through its wholly owned subsidiary, Biospectrum Technologies, holds revolutionary patented technologies that can potentially re-vitalize the diagnostics industry. The first product is the patented High Throughput Screening-Magnetic Testing Platform (HTS-MTP) diagnostic system. The Company believes that clinical trials will confirm that the system will offer the medical industry a unique method that provides confirmatory and viral load diagnostics at the same cost of screening assays. It is also expected that the HTS-MTP will detect any virus or bacteria and count the viral load in a matter of minutes and has the capabilities of screening several hundred percent more assays per hour at a fraction of the cost of current technologies.
The HTS-MTP patented diagnostics system uses Magnetic Resistance (MR) sensors integrated into the company's exclusive technology providing High Throughput Screening (HTS) with the company's proprietary immunoassays incorporating super paramagnetic or ferromagnetic micro-spheres in a ternary complex. The company's initial immunoassays, to be developed, will target the HIV and Hepatitis B viruses.
The company defines its markets for its first line of products as public/private laboratories and blood banks worldwide. According to S & P's Industry Surveys, Biotechnology, December 29, 2005 revenues for all publicly traded biotech companies (US and non-US biotech-related concerns trading on major US stock markets) are expected to reach $50 billion in 2005
BMGC Took a bite at 1.06
LMAO
Dare I say IPRE buys coming in...
Printing it today!!
TNOG Sweeeet!!
AMEP .116x.117
AMEP Oil News
American Energy Production Inc. Announces ``It Rained''
Tuesday May 2, 10:30 am ET
MINERAL WELLS, Texas--(BUSINESS WIRE)--May 2, 2006--American Energy Production Inc. (OTCBB:AMEP - News) announced today a major rainfall on wholly owned Bend Arch Petroleum Inc. Palo Pinto 12 well leases in Palo Pinto County, Texas.
ADVERTISEMENT
Charles Bitters, President of American Energy Production Inc., stated, "This may be one of the most important news releases AMEP has made in the past year for Bend Arch Petroleum Inc. The area around North Texas, especially Palo Pinto County hasn't had measurable rainfall for over one year resulting in a shortage of fresh water to fracture stimulate the Barnett Shale and Marble Falls formations currently in production. With over 3.5 inches of rain the creeks close to the property are running and the stock tanks are almost full. Having this volume of fresh water available Bend Arch can immediately make plans to get on the service companies list to begin frac operations."
The first well Bend Arch plans to fracture stimulate is the Hart #2 Marble Falls oil and natural gas producer. This well was originally fracture stimulated with a small 2600 barrel slick water frac in early 2005 and immediately produced 1000 barrels of oil in the first week of production. The Company believes by fracting with 8000 to 10000 barrels of slick water this well has the potential to make more oil and natural gas for an extended period of time.
A unidrolics jet pump assembly was installed on the Bend Arch Petroleum Hart #8 well on May 1st and as soon as storage tanks are delivered the gas well will be put into production. The unidrolics pump will help remove the fracture fluid still to be recovered from the well faster than a conventional pumping unit.
Bend Arch Petroleum's Phantom Rig I has commenced drilling on the Murphy #3 and 8 5/8" surface pipe has been cemented in place. The Company is very excited about this prospect well because of the seismic data retrieved from the extensive seismic shoot done in 2005 by Bend Arch Petroleum Inc.
MOOOOOO!!!
In AMEP
AMEP looking good
CRTX, creeping up on news
FPPL, mini shake over
IN CRTX
Hello Bill
AURC gapper.38x.39
MOOOOOO to that!!
Way to MOOOOO Bill!!
HEC running
Im tucking UPDA in for the night, needs the rest for the trip(UP) I hope
Night MOOOOVERS, Nap time